Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Resonant Sensors Incorporated (RSI) is a biotechnology company specializing in high-throughput, label-free optical biosensor systems for biochemical analysis and medical diagnostics. The company's core technology is based on proprietary Guided-Mode Resonance (GMR), which enables real-time, high-precision measurements of biomolecular interactions without the need for fluorescent or radioactive labels. RSI's flagship product, the ResoSens Ultra-Mab Pro, is a benchtop plate reader designed to accelerate antibody discovery and characterization by providing kinetic binding data in a standard 96-well format. The company also offers disposable Bionetic sensor plates and specialized reagents, such as peptide/HLA monomers and tetramers, to support immunotherapy research. Headquartered in Arlington, Texas, RSI serves the pharmaceutical and biotechnology industries by streamlining drug discovery, industrial screening, and preclinical research.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Resonant Sensors.